guidanc pharmedium updat
key factor go
focu turn pharmedium guidanc industri trend set report
result wed may bmo key call pharmedium
busi voluntarili close dec recal publish deeper dive
pharmedium busi trim ep deeper dive
pharmedium due memphi facil open timelin
indic management abc guidanc see op profit growth
focu due pharmedium closur addit expens
relat remedi work need done facil separ sens
brand mfr econom may becom topic may impact abc
guidanc note trend actual favor
qtr could ok see ep vs street see post ep
street brand inflat larg come strong average inflat
rate come year ago level note gener deflat persist
high singl digit rang although off-set somewhat strong flu season gener
tamiflu gener launch front mln worth gener
launch qtr yr ago bln howev one
gener launch palonostron gener aloxi could posit drug
management specif call expect gener launch origin delay
detail model assumpt figur note result
close watch assess trend three drug distributor updat
pharmedium abc guidanc like drive stock guidanc histori
shown figur also look hear color chang brand drug
econom gener deflat pt base ep
quarterli annual ep usd
consensu number thomson reuter receiv gmt
barclay capit inc and/or one affili seek busi
compani cover research report result investor awar
firm may conflict interest could affect object report investor
consid report singl factor make invest decis
return equiti ttm
link barclay live interact chart
equal weight compani
gain share via largest custom walgreen
compani continu face headwind
throughout relat gener price deflat
believ persist hamper ep growth
upsid case see modest multipl expans
gener price deflat come better fear
would lead multipl ep
downsid case see continu persist
gener deflat continu problem
pharmedium bring compani peer
group
margin return data
balanc sheet cash flow mn
equival
short long-term debt
chang work capit
flow oper
valuat leverag metric
 annual revenu model mil abcabcabcabcabcrevenu revenueabdc drug specialti distribut global commerci servic anim growthabdc drug specialti distribut global commerci servic anim total revsabdc drug specialti distribut global commerci servic anim annual gross profit mil abcabcabcabcabcgross profit gross profit formula pharma distribut strateg global global commerci servic anim incom gross growthpharma distribut strateg global global commerci servic anim incom charg nmnmnmnmnmnmnmnmtotal gross gp margin press releas pharma distribut strateg global global commerci servic anim incom charg nmnmnmnmnmnmnmnmtotal gross profit annual oper profit mil abcabcabcabcabcoper profit ebit ebitpharma distribut strateg global global commerci servic anim incom growthpharma distribut strateg global global commerci servic anim incom charg nmnmnmnmnmnmnmnmtotal ebit ebit marginpharma distribut strateg global global commerci servic anim incom ebit barclay corp
 quarterli incom statement mil ep ep ep ep distribut sell oper addback check excl intang asset ens rate check ep fulli dilut share growth distribut sell per barclay corp
 servic profit profit profit marginsdown bpstax changeshar repurchaseoffset dilutionoffset dilutionoffset milgener new genericscontribut new genericscontribut new genericssimilar prior yearsimilar prior yearsimilar prior yearno signific contribut biosimsno signific contribut biosimsno signific contribut biosimshd smith acquisit includedhd smith acquisit includ barclay corp
steve valiquett herebi certifi view express research report accur reflect person view
subject secur issuer refer research report part compens directli indirectli relat
specif recommend view express research report
barclay research produc invest bank barclay bank plc affili collect individu barclay
avail disclosur
compani subject research report current import disclosur regard compani pleas refer
http //publicresearch barclay com altern send written request barclay research complianc seventh avenu floor
new york ny call
analyst respons prepar research report receiv compens base upon variou factor includ firm total
revenu portion gener invest bank activ profit revenu market busi
potenti interest firm invest client research respect asset class cover analyst
author contribut research report research analyst unless otherwis indic
public date top report reflect local time report produc may differ releas date provid
gmt
analyst regularli conduct site visit view materi oper cover compani barclay polici prohibit accept
payment reimburs cover compani travel expens visit
http //publicresearch barcap com/s/rd htm order access barclay research conflict manag polici statement pleas refer
procedur pleas
barclay research depart produc variou type research includ limit fundament analysi equity-link analysi
quantit analysi trade idea recommend contain one type barclay research may differ contain
type barclay research whether result differ time horizon methodolog otherwis barclay research depart
oper independ absa research depart absa research produc absa bank limit act corpor
invest bank divis part barclay africa group limit affili invest bank barclay bank plc elig
client may receiv research report research depart may reach differ conclus may contain differ
conflict forecast recommend trade idea
price sourc thomson reuter last avail close price relev trade market unless anoth time sourc
